Evotec SE has announced the nomination of a small-molecule preclinical development candidate from its multi-target drug discovery alliance in medical dermatology with Almirall SA. The program is aimed at developing novel treatments for immune-mediated inflammatory skin diseases with high unmet medical need. The collaboration, established in 2022, leverages Evotec’s fully integrated, AI/machine learning enhanced discovery and preclinical development platforms.
Almirall SA has nominated LAD-116 as a novel therapy targeting non-melanoma skin cancer for further development in IND-enabling studies. LAD-116 is based on collaborator Etherna Immunotherapies NV’s intratumoral mRNA/lipid nanoparticle (LNP) platform.
Almirall SA has submitted a CTA filing for a bispecific antibody targeting IL-13 and OX-40L for the treatment of atopic dermatitis. The company expects to initiate a first-in-human phase I trial during the first half of this year.
The industry has been complaining about the drug pricing and reimbursement policies of European governments for years, but only now with the Trump administration’s moves to enforce most favored nation (MFN) pricing and reduce the U.S./EU price gap are governments facing up to the reality that they will have to pay more for new drugs.
Almirall SA has disclosed tyrosine-protein kinase ITK/TSK (EMT) inhibitors reported to be useful for the treatment of atopic dermatitis, psoriasis, alopecia areata, vitiligo, T-cell lymphoma, asthma, inflammatory bowel disease and multiple sclerosis, among others.
Almirall S.A. has entered into an exclusive license agreement with Novo Nordisk A/S for global rights to develop and commercialize the IL-21-blocking monoclonal antibody NN-8828 in certain fields, including immune inflammatory dermatological diseases.
Heterobicyclic derivatives characterized as tyrosine-protein kinase ITK/TSK (EMT) inhibitors have been revealed in an Almirall SA patent. They are reported to be useful for the treatment of atopic dermatitis, psoriasis, T-cell lymphoma, alopecia areata and vitiligo.
Researchers from Almirall SA and affiliated organizations reported the discovery and preclinical characterization of LAS-200813, a novel peptide inhibitor of the Keap1-Nrf2 protein-protein interaction.
Simcere Pharmaceutical Group has out-licensed its autoimmune drug candidate SIM-0278 for all indications to Almirall SA in a deal worth up to $507 million. Simcere granted exclusive global rights to the candidate to Almirall for development and commercialization excluding mainland China, Hong Kong, Macau, and Taiwan. In return, Almirall will pay Simcere $15 million up front.
Simcere Pharmaceutical Group has out-licensed its autoimmune drug candidate SIM-0278 for all indications to Almirall SA in a deal worth up to $507 million. Simcere granted exclusive global rights to the candidate to Almirall for development and commercialization excluding mainland China, Hong Kong, Macau, and Taiwan. In return, Almirall will pay Simcere $15 million up front.
